900
Participants
Start Date
May 2, 2018
Primary Completion Date
August 1, 2026
Study Completion Date
August 1, 2026
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq
Early Aggressive Therapy
Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Traditional Therapy
New York University School of Medicine, New York
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center, New York
Allegheny Health Network Research Institute, Pittsburgh
Geisinger Clinic, Danville
Christiana Care Health Services, Inc., Newark
Georgetown University, Washington D.C.
University of Maryland, Baltimore, Baltimore
The Johns Hopkins Hospital, Baltimore
Neurology Consultants of Tidewater, Norfolk
Blacksburg Neurology, Christiansburg
University of Florida, Gainesville
University of Miami, Miami
University of South Florida Health, Tampa
University of Alabama at Birmingham, Birmingham
The University of South Alabama, Mobile
Vanderbilt Comprehensive MS Center, Nashville
Norton Neurology MS Services, Louisville
OhioHealth Research Institute, Columbus
University of Cincinnati, Cincinnati
University of Michigan, Ann Arbor
Wayne State University, Detroit
Medical College of Wisconsin, Milwaukee
Mayo Clinic, Rochester
Billings Clinic, Billings
Advanced Neurology Specialists, Great Falls
Rush University Medical Center, Chicago
The University of Kansas Medical Center (KUMC), Kansas City
University of Nebraska Medical Center, Omaha
Oklahoma Medical Research Foundation, Oklahoma City
Baylor Scott and White Health, Dallas
Central Texas Neurology Consultants, Round Rock
University of Utah, Salt Lake City
St. Joseph's Hospital & Medical Center - Barrow Neurological Institute, Phoenix
Cedars-Sinai Medical Center, Los Angeles
University of California, Los Angeles, Los Angeles
University of California, San Diego, San Diego
University of California, San Francisco, San Francisco
CommonSpirit Health Research Institute, Carmichael
Providence Health and Services - Oregon, Portland
Swedish Health Services, Seattle
University of Washington, Seattle
Massachusetts General Hospital, Boston
University of Massachusetts Medical School, Worcester
Hackensack University Medical Center, Hackensack
University of Texas Southwestern Medical Center, Dallas
The University of Vermont and State Agricultural College, Burlington
Patient-Centered Outcomes Research Institute
OTHER
National Multiple Sclerosis Society
OTHER
Johns Hopkins University
OTHER